 |
 |
|
|
RESÚMENES AGOSTO 2004 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
Mary V. Seeman
Am J Psychiatry 161:1324-1333, August 2004
Stephen R. Marder, Susan M. Essock, Alexander L. Miller, Robert W. Buchanan, Daniel E.
Casey, John M. Davis, John M. Kane, Jeffrey A. Lieberman, Nina R. Schooler, Nancy Covell, Scott
Stroup, Ellen M. Weissman, Donna A. Wirshing, Catherine S. Hall, Leonard Pogach,
Xavier Pi-Sunyer, J. Thomas Bigger, Jr., Alan
Friedman, David Kleinberg, Steven J. Yevich, Bonnie
Davis, and Steven Shon
Am J Psychiatry 161:1334-1349, August 2004
Prolactin levels in antipsychotic treatment of
patients with schizophrenia carrying the DRD2*A1 allele
ROSS McD. YOUNG, BRUCE R.
LAWFORD, MARK BARNES, TERRY RITCHIE, WARREN K. WARD, ERNEST P. NOBLE
The British Journal of Psychiatry (2004) 185: 147-151
Alan A. Woodall, David B. Menkes,
Thomas R. Trevelyan, Colin P. Lanceley
Psychiatric Bulletin (2004) 28: 285-288
Alan S. Brown, Melissa D. Begg,
Stefan Gravenstein, Catherine A. Schaefer, Richard J.
Wyatt, Michaeline Bresnahan,
Vicki P. Babulas, Ezra S. Susser
Arch Gen Psychiatry. 2004;61:774-780.
Oral risperidone
plus oral lorazepam versus standard care with
intramuscular conventional neuroleptics in the
initial phase of treating individuals with acute psychosis.
Lejeune, Joseph; Larmo, Ilkka; Chrzanowski,
Wlodzimierz; Witte, Roel; Karavatos, Athanasios; Schreiner,
Andreas; Lex, Alice; Medori,
Rossella
International Clinical
Psychopharmacology. 19(5):259-269,
September 2004
Antipsychotic drugs in mania: factors predicting
use of antipsychotic medication following inpatient treatment of mania.
Samellas, Dimitris; Read, Priscilla; Cookson,
John C
International Clinical
Psychopharmacology. 19(5):291-297,
September 2004
Serum prolactin levels in unmedicated
first-episode and recurrent schizophrenia patients: a possible marker for the
disease's subtypes
Michael
Segal, Avi Avital, Marina
Rojas, Noemi Hausvater,
Sergio Sandbank, David Liba, Leonardo Moguillansky, Ilana Tal and Abraham Weizman
Psychiatry
Research .Volume 127, Issue 3, 15 July 2004, Pages 227-235
Relationships of Age at Onset With Clinical Features and Cognitive Functions in a Sample
of Schizophrenia Patients
Silvio Bellino, Paola Rocca,
Luca Patria, Livio Marchiaro, Roberta Rasetti, Rossella Di Lorenzo, Erika Paradiso, and Filippo
Bogetto
J Clin Psychiatry 2004;65:908-914
Quality of Life in Schizophrenia: The
Impact of Psychopathology, Attitude Toward Medication,
and Side Effects
Alex Hofer,
Georg Kemmler, Ursula Eder, Monika Edlinger, Martina
Hummer, and W. Wolfgang Fleischhacker
J Clin Psychiatry 2004;65:932-939
Changes in Serum Interleukin-2, -6, and
-8 Levels Before and During Treatment With Risperidone and Haloperidol: Relationship to Outcome in
Schizophrenia
Xiang Yang Zhang, Dong Feng Zhou, Lian Yuan Cao, Pei Yan
Zhang, Gui Ying Wu, and Yu Cun
Shen
J Clin Psychiatry 2004;65:940-947
A new atypical antipsychotic: quetiapine-induced
sexual dysfunctions.
Atmaca M, Kuloglu
M, Tezcan E.
Int J Impot Res. 2004 Jul 29 [Epub ahead of print]
A comparison of type 2 diabetes outcomes among persons with and
without severe mental illnesses.
Dixon LB, Kreyenbuhl JA, Dickerson FB, Donner
TW, Brown CH, Wolheiter K, Postrado
L, Goldberg RW, Fang L, Marano C, Messias
E.
Psychiatr Serv. 2004 Aug;55(8):892-900
Switching elderly chronic psychotic patients to olanzapine.
Barak Y, Shamir E, Mirecki I, Weizman R, Aizenberg D.
International Journal of Neuropsychopharmacology
2004;7(2):165-169
Resting metabolic rate in people taking atypical antipsychotic
medication.
Sharpe JK, Hills
AP, Byrne NM, Stedman TJ.
Asia Pac J Clin
Nutr. 2004;13(Suppl):S157.
Executive dysfunctions in schizophrenia. Relationships to clinical manifestation
R. C. K. Chan,
E. Y. H. Chen, E. F. C. Cheung and
H. K. Cheung
European Archives of Psychiatry and Clinical
Neuroscience 2004; Volume 254, Number 4: 256 - 262
Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A
receptors?
Tyson PJ,
Roberts KH, Mortimer AM.
Int J Neurosci. 2004 Jun;114(6):593-611.
Olanzapine plus fluvoxamine
and olanzapine alone for the treatment of an acute exacerbation of
schizophrenia.
Chaichan W.
Psychiatry Clin
Neurosci.
2004 Aug;58(4):364-368.
Adjunctive Fluvoxamine
Inhibits Clozapine-Related Weight Gain and Metabolic
Disturbances.
Lu ML, Lane HY, Lin SK, Chen KP, Chang WH.
J Clin
Psychiatry. 2004 Jun;65(6):766-771.
Shitij Kapur
Trends in Pharmacological Sciences. Volume 25, Issue 8, 1 August 2004, Pages 402-406
Early Clinical Experience With Risperidone Long-Acting
Injection: A Prospective, 6-Month Follow-Up of 100 Patients
David M.
Taylor, Corina L. Young, Shubhra
Mace, and Maxine X. Patel
J Clin Psychiatry 2004;65:1076-1083
Safety and Efficacy of Long-Acting Risperidone in Schizophrenia: A 12-Week, Multicenter, Open-Label Study in Stable Patients Switched
From Typical and Atypical Oral Antipsychotics
Jean-Pierre
Lindenmayer, Els Eerdekens, Sally A. Berry, and Marielle
Eerdekens
J Clin Psychiatry 2004;65:1084-1089
Stefan Weinmann, Birgit Janssen, and Wolfgang Gaebel
J Clin Psychiatry 2004;65:1099-1105
Sheila Botts, Robert Littrell, and Jose
de Leon
J Clin Psychiatry 2004;65:1138-1143
Psychopharmacology
2004; Volume 174, Number 4: 477 - 489
Guidelines
for prevention and treatment of adverse effects of antipsychotic drugs on
glucose–insulin homeostasis and lipid metabolism
K. I. Melkersson,
M.-L. Dahl and A.-L. Hulting
Psychopharmacology 2004; Volume 175, Number 1: 1
- 6
FAUC
213, a highly selective dopamine D4 receptor full antagonist,
exhibits atypical antipsychotic properties in behavioural
and neurochemical models of schizophrenia
Frank Boeckler, Holger Russig, Weining Zhang,
Stefan Löber, John Schetz, Harald Hübner, Boris Ferger,
Peter Gmeiner and Joram Feldon
Psychopharmacology 2004; Volume 175, Number
1: 7 - 17
A
preliminary report on dopamine system reactivity in PKU: acute effects of
haloperidol on neuropsychological, physiological, and neuroendocrine
functions
Monica Luciana,
Karen L. Hanson and
Psychopharmacology
2004; Volume 175, Number 1: 18 - 25
Louis-Éric Trudeau
J Psychiatry Neurosci. 2004 July; 29 (4): 296–310
Can J Psychiatry 2004;49:476–479
The
relationship between brain structure and neurocognition
in schizophrenia: a selective review
Elena Antonova, Tonmoy Sharma, Robin Morris
and Veena Kumari
Correlates of insight
in first episode psychosis
Matcheri S. Keshavan,
Jonathan Rabinowitz, Goedele
DeSmedt, Phillip D. Harvey and Nina Schooler
Neuropsychological
deficits are associated with smoking cessation treatment failure in patients
with schizophrenia
Sara L.
Dolan, Kristi A. Sacco, Angelo Termine,
Aisha A. Seyal, Melissa M. Dudas, Jennifer C. Vessicchio,
Bruce E. Wexler and Tony P. George
Elvira Bramon, Sophia Rabe-Hesketh, Pak
Sham, Robin M. Murray and Sophia Frangou
Michael F. Egan, Richard E. Straub, Terry E. Goldberg, Imtiaz Yakub, Joseph H. Callicott, Ahmad R. Hariri, Venkata S. Mattay, Alessandro Bertolino, Thomas M. Hyde, Cynthia Shannon-Weickert, Mayada Akil, Jeremy Crook, Radha Krishna
Vakkalanka, Rishi Balkissoon, Richard A. Gibbs, Joel E. Kleinman
and Daniel R. Weinberger
PNAS | August 24, 2004 | vol.
101 | no. 34 | 12604-12609
Paul S. Appelbaum, Pamela
Clark Robbins, Roumen Vesselinov
Comprehensive
Psychiatry.
September-October 2004 • Volume 45 • Number 5
Genetic
dissection of drug effects in clinical practice: CLOCK gene and clozapine-induced diurnal sleepiness
Enrico Lattuada, Roberto Cavallaro, Francesco Benedetti, Federica Cocchi,
Cristina Lorenzi and Enrico Smeraldi
Neuroscience
Letters. Volume 367, Issue 2, 2 September 2004, Pages 152-155
Approaching
a consensus cognitive battery for clinical trials in schizophrenia: The
NIMH-MATRICS conference to select cognitive domains and test criteria
Michael F. Green, Keith H. Nuechterlein, James M. Gold, Deanna M. Barch, Jonathan Cohen, Susan Essock, Wayne S. Fenton, Fred Frese, Terry E. Goldberg, Robert K. Heaton, Richard S.E. Keefe, Robert S. Kern, Helena Kraemerj
, Ellen Stover, Daniel R. Weinberger, Steven Zalcman and Stephen R. Marder